PURPOSE: Nomograms have been developed to allow the prediction of disease recurrence based on clinical and pathological parameters in patients with clinically localized prostate cancer. However, they have been constructed using predominantly white American male (CAM) cohorts. We have previously shown that black American males (AAMs) have worse disease-free survival after radical prostatectomy after controlling for known prognostic factors. We tested the accuracy of prognostic nomograms in a population of AAMs with prostate cancer treated with radical prostatectomy. MATERIALS AND METHODS: We tested the performance of published preoperative and postoperative prognostic nomograms in a cohort of patients treated with radical prostatectomy as monotherapy for localized prostate cancer at Wayne State University in the prostate specific antigen era. Predictions made with the nomogram were stratified by race and compared with actual outcomes. The summary statistic used to evaluate the nomogram was the concordance index. A value of 0.5 indicates no predictive discrimination, whereas a value of 1.0 indicates perfect discrimination. RESULTS: A total of 1,043 patients, including 331 AAMs (32%) and 712 CAMs (68%), comprised the study cohort. Treatment failure was defined as increasing prostate specific antigen, which occurred in 193 patients (18.5%). The preoperative concordance index for CAMs and AAMs was 0.78 and 0.74, respectively (p = 0.8). The postoperative index was 0.85 and 0.83, respectively (p = 0.9). CONCLUSIONS: Preoperative and postoperative nomograms can be applied accurately to an individual regardless of race.
PURPOSE: Nomograms have been developed to allow the prediction of disease recurrence based on clinical and pathological parameters in patients with clinically localized prostate cancer. However, they have been constructed using predominantly white American male (CAM) cohorts. We have previously shown that black American males (AAMs) have worse disease-free survival after radical prostatectomy after controlling for known prognostic factors. We tested the accuracy of prognostic nomograms in a population of AAMs with prostate cancer treated with radical prostatectomy. MATERIALS AND METHODS: We tested the performance of published preoperative and postoperative prognostic nomograms in a cohort of patients treated with radical prostatectomy as monotherapy for localized prostate cancer at Wayne State University in the prostate specific antigen era. Predictions made with the nomogram were stratified by race and compared with actual outcomes. The summary statistic used to evaluate the nomogram was the concordance index. A value of 0.5 indicates no predictive discrimination, whereas a value of 1.0 indicates perfect discrimination. RESULTS: A total of 1,043 patients, including 331 AAMs (32%) and 712 CAMs (68%), comprised the study cohort. Treatment failure was defined as increasing prostate specific antigen, which occurred in 193 patients (18.5%). The preoperative concordance index for CAMs and AAMs was 0.78 and 0.74, respectively (p = 0.8). The postoperative index was 0.85 and 0.83, respectively (p = 0.9). CONCLUSIONS: Preoperative and postoperative nomograms can be applied accurately to an individual regardless of race.
Authors: Rochelle Payne Ondracek; Michael W Kattan; Christine Murekeyisoni; Changhong Yu; Eric C Kauffman; James R Marshall; James L Mohler Journal: J Natl Compr Canc Netw Date: 2016-11 Impact factor: 11.908
Authors: Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Christopher J DiBlasio; Alwyn Reuther; Eric A Klein; Michael W Kattan Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Paul A Fearn; Michael W Kattan Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino Journal: Future Oncol Date: 2009-12 Impact factor: 3.404
Authors: Amita Shukla-Dave; Hedvig Hricak; Nicole Ishill; Chaya S Moskowitz; Marija Drobnjak; Victor E Reuter; Kristen L Zakian; Peter T Scardino; Carlos Cordon-Cardo Journal: Clin Cancer Res Date: 2009-05-12 Impact factor: 12.531
Authors: D M Moreira; J C Presti; W J Aronson; M K Terris; C J Kane; C L Amling; L L Sun; J W Moul; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2009-11-17 Impact factor: 5.554